AxoGen (NASDAQ: AXGN) reported Q1 EPS of $0.07, $0.01 worse than the analyst estimate of $0.08. Revenue for the quarter came in at $61.46 million versus the consensus estimate of $57.85 million.

Guidance:
We expect 2026 revenue growth to be at least 20%, or $270 million, for the full-year and gross margin to be in the range of 74% to 76%. Additionally, we expect to be free cash flow positive for the full-year.

For earnings history and earnings-related data on AxoGen (AXGN) click here.